Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

Stamatouli, Angeliki M., Quandt, Zoe, Perdigoto, Ana Luisa, Clark, Pamela L., Kluger, Harriet, Weiss, Sarah A., Gettinger, Scott, Sznol, Mario, Young, Arabella, Rushakoff, Robert, Lee, James, Bluestone, Jeffrey A., Anderson, Mark, Herold, Kevan C.·2018·Diabetes

DOI 10.2337/dbi18-0002

Cited by (594)

Items 101–200 of 594

The dark side of immunotherapy
Nwanneka Okwundu, Douglas Grossman, Siwen Hu‐Lieskovan, Kenneth F. Grossmann, Umang Swami · 2021 · Annals of Translational Medicine
Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors
David König, Heinz Philipp Laubli · 2020 · Pharmacology
Identification of Immune Checkpoint Inhibitor–Induced Diabetes
Karina Nicole Ruiz-Esteves, KAITLYN R. SHANK, Aaron J. Deutsch, Alekhya Gunturi, Natalia Chamorro-Pareja, Caitlin Colling, Leyre Zubiri, Katherine Perlman, Tianqi Ouyang, Alexandra–Chloé Villani et al. · 2024 · JAMA Oncology
Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors
Shintaro Iwama, Tomoko Kobayashi, Hiroshi Arima · 2025 · Nature Reviews Endocrinology
American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach
Kevin C.J. Yuen, Susan Leanne Samson, Irina Bancos, Aidar R. Gosmanov, Sina Jasim, Leslie Anne Fecher, Jeffrey S. Weber · 2022 · Endocrine Practice
Pathobionts from chemically disrupted gut microbiota induce insulin-dependent diabetes in mice
Xin Yang, Zhiyi Wang, Junling Niu, Rui Zhai, Xinhe Xue, Guojun Gary Wu, Yuanyuan Fang, Guangxun Meng, Huijuan Yuan, Liping Zhao et al. · 2023 · Microbiome
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
Linda Wu, Venessa Tsang, Sarah Christina Sasson, Alexander Maxwell Menzies, Matteo Salvatore Carlino, David Alexander Brown, Roderick John Clifton-Bligh, Jenny Elizabeth Gunton · 2021 · Frontiers in Endocrinology
Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline
Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Masahiko Ando, Xin Zhou, Ayana Yamagami, Takeshi Onoue, Yohei Kawaguchi et al. · 2021 · The Journal of Clinical Endocrinology & Metabolism
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
David Wai-Meng Tai, Su Pin Choo, Valerie Chew · 2019 · Cancers
Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports
Marco Zezza, Christophe Kosinski, Carine Mekoguem, Laura Marino, Haïthem Chtioui, Nelly Pitteloud, Faïza Lamine · 2019 · BMC Endocrine Disorders
Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism
Diane Mourad, Nadim S. Azar, Assaad Antoine Eid, Sami T. Azar · 2021 · International Journal of Molecular Sciences
Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study
Dominik J. Ose, Richard H. Viskochil, Andreana Natalie Holowatyj, Mikaela Larson, Dalton Wilson, William A. Dunson, Vikrant G. Deshmukh, J. Ryan Butcher, Belinda Taylor, Kim Svoboda et al. · 2021 · Journal of the National Comprehensive Cancer Network
Harnessing prostaglandin E2 signaling to ameliorate autoimmunity
Juliann B. Burkett, Amanda C. Doran, MAUREEN A. GANNON · 2023 · Trends in Immunology
Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes
Ciriana Orabona, Giada Mondanelli, Paolo Puccetti, Ursula Grohmann · 2018 · Trends in Molecular Medicine
Modeling human T1D-associated autoimmune processes
Mohsen Khosravi Maharlooei, Rachel Madley, Chiara Borsotti, Leonardo M. R. Ferreira, Robert C. Sharp, Michael A. Brehm, Dale L. Greiner, Audrey V. Parent, Mark Stuart Anderson, Megan Sykes et al. · 2021 · Molecular Metabolism
Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma
Halis Kaan Aktürk, Kasey L. Couts, Erin E. Baschal, Kagan Ege Karakus, Robert J. Van Gulick, Jacqueline A. Turner, Laura L. Pyle, William Allen Robinson, Aaron W. Michels · 2022 · JAMA Network Open
Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
Yong-Qiang Ao, Jian Gao, Shuai Wang, Jia-Hao Jiang, Jie Deng, Haikun Wang, Bei Xu, Jian‐Yong Ding · 2023 · Molecular Cancer
Role of the PD‐1/PD‐L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions
Yan Mi, Jinming Han, Jie Zhu, Tao Jin · 2021 · Molecular Neurobiology
Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review
Michele Porcu, Cinzia Solinas, Cristina Migali, Angelo Battaglia, Marina Schena, Lorenzo Mannelli, Alfredo Addeo, Karen E Willard-Gallo, Luca Saba · 2020 · Targeted Oncology
Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy
Afaf Abed, Ngie Law, Leslie Calapre, Johnny Lo, Vikas Bhat, Samantha Elizabeth Bowyer, Michael Millward, Elin Solomonovna Gray · 2022 · European Journal of Cancer
Immune Cells Gate White Adipose Tissue Expansion
Aaron R. Cox, Natasha Chernis, Peter M. Masschelin, Sean Michael Hartig · 2019 · Endocrinology
Islet–immune interactions in type 1 diabetes: the nexus of beta cell destruction
Leeana D. Peters, Amanda L. Posgai, Todd M. Brusko · 2019 · Clinical & Experimental Immunology
Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors
Shintaro Iwama, Tomoko Kobayashi, Hiroshi Arima · 2021 · Endocrinology and Metabolism
Association between pretreatment neutrophil‐to‐lymphocyte ratio and immune‐related adverse events due to immune checkpoint inhibitors in patients with non‐small cell lung cancer
Airi Fujimoto, Gouji Toyokawa, Yoshimichi Koutake, Shigeru Kimura, Yosei Kawamata, Kazuhisa Fukuishi, Koji Yamazaki, Sadanori Takeo · 2021 · Thoracic Cancer
Type I interferons as key players in pancreatic β-cell dysfunction in type 1 diabetes
Laura Marroquí, Atenea Alexandra Perez-Serna, Ignacio Babiloni-Chust, Reinaldo Sousa dos Santos · 2021 · International review of cytology
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
Rachel S. Goodman, Seungyeon Jung, Justin Micah Balko, Douglas Buckner Johnson · 2023 · Immunological Reviews
Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy
Apoorva Mehta, Mateen Motavaf, Ikenna David Nebo, Sophia Luyten, Kofi D. Osei-Opare, Alejandro Ariel Gru · 2025 · Journal of Clinical Medicine
PD-1 and PD-L1 Expression in Peripheral CD4/CD8+ T Cells Is Restored in the Partial Remission Phase in Type 1 Diabetes
Xia Li, Ting Zhong, Rong Tang, Chao Wu, Yuting Xie, Fang Liu, Zhiguang Zhou · 2020 · The Journal of Clinical Endocrinology & Metabolism
A Century-long Journey From the Discovery of Insulin to the Implantation of Stem Cell–derived Islets
Adam Ramzy, Paul J. Belmonte, Mitchell J.S. Braam, Shogo Ida, Emily M. Wilts, Megan K. Levings, Alireza Rezania, Timothy J. Kieffer · 2022 · Endocrine Reviews
Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline.
Zhou, Xin, Iwama, Shintaro, Kobayashi, Tomoko, Ando, Masahiko, Arima, Hiroshi · 2023 · The Journal of Clinical Endocrinology & Metabolism
Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus
Dehua Liao, Chaoyi Liu, Shanshan Chen, Fen Liu, Wei Li, Dangang Shangguan, Yingrui Shi · 2023 · International Immunopharmacology
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Weilei Hu, Guosheng Wang, Yian Wang, Matthew John Riese, Ming You · 2020 · iScience
The Role of T Cell Receptor Signaling in the Development of Type 1 Diabetes
Matthew Clark, Charles J. Kroger, Ke Qi, Roland Tisch · 2021 · Frontiers in Immunology
Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events
James William Smithy, David M. Faleck, Michael Andrew Postow · 2021 · Clinical Cancer Research
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities
Tim Cooksley, Monica Girotra, Pamela Ginex, Ruth Ann Gordon, Ronald Anderson, Ada Gabriela Blidner, Jennifer Nam Choi, Michael Lawrence Dougan, Ilya G. Glezerman, Dipti Gupta et al. · 2020 · Supportive Care in Cancer
Type 1 diabetes related to immune checkpoint inhibitors
Megumi Tachibana, Akihisa Imagawa · 2022 · Best Practice & Research Clinical Endocrinology & Metabolism
Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, Dhruv Bansal · 2024 · Cancers
Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature
Ashray Gunjur, Oliver Klein, Damien Kee, Jonathan Simon Cebon · 2019 · Journal for ImmunoTherapy of Cancer
Current cancer therapies and their influence on glucose control
Carly Yim, Kerry D. Mansell, Nassrein Hussein, Terra Arnason · 2021 · World Journal of Diabetes
Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
Yuqing He, Mengyao Lu, Jing Che, Qian Chu, Peng Zhang, Yuan Chen · 2021 · Frontiers in Oncology
Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases
Yoshiaki Yura, Masakazu Hamada · 2022 · Cancers
Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper
Nicola Silvestris, Tindara Franchina, Marco Gallo, Antonella Argentiero, Angelo Avogaro, Giuseppe Cirino, Annamaria Anita Livia Colao, Romano Danesi, Graziano Di Cianni, Stella D’Oronzo et al. · 2023 · ESMO Open
Cancer immunotherapies repurposed for use in autoimmunity
Dominic A. Boardman, Megan K. Levings · 2019 · Nature Biomedical Engineering
Diabetes mellitus induced by immune checkpoint inhibitors
Zhenjiang Zheng, Ya Liu, Jie Yang, Chunlu Tan, Li Zhou, Xing Wang, Xiao Li, Shu Zhang, Yonghua Chen, Xubao Liu · 2020 · Diabetes/Metabolism Research and Reviews
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy
Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, Domenico Milardi, Laura De Marinis, Alfredo Pontecorvi · 2021 · Trends in Endocrinology and Metabolism
Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors
Hidefumi Inaba, Yosuke Kaido, Saya Ito, Tomonao Hirobata, Gen Inoue, Takakazu Sugita, Yuki Yamamoto, Masatoshi Jinnin, Hiroaki J. Kimura, Tomoko Kobayashi et al. · 2022 · Endocrinology and Metabolism
Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction
Jordan J Wright, Douglas Buckner Johnson · 2022 · The Journal of Clinical Endocrinology & Metabolism
Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses
Jacopo Canzian, Fabio Conforti, Flavia Jacobs, C. Benvenuti, Mariangela Gaudio, Riccardo Gerosa, Rita De Sanctis, Alberto Zambelli · 2025 · Cancers
Predictive biomarkers of response to immune checkpoint inhibitors in melanoma
Caroline A. Nebhan, Douglas Buckner Johnson · 2020 · Expert Review of Anticancer Therapy
Molecular Footprints of the Immune Assault on Pancreatic Beta Cells in Type 1 Diabetes
Máikel L. Colli, Florian Szymczak, Decio Laks Eizirik · 2020 · Frontiers in Endocrinology
Biomarkers and risk factors for the early prediction of immune-related adverse events: a review
Ying Zhang, Xiaoling Zhang, Weiling Li, Yunyi Du, Wenqing Hu, Jun Zhao · 2022 · Human Vaccines & Immunotherapeutics
Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus
Jian Zhu, Junfeng Han, Liehua Liu, Yu Liu, Wen Xu, Xiaomu Li, Lin Yang, Yong Gu, Wei Tang, Yongquan Shi et al. · 2023 · Diabetes Research and Clinical Practice
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome
John Marsiglio, Jordan P. McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami, Douglas Grossman, Alyssa Erickson‐Wayman, Heloisa Prado Soares, Katie Kerrigan et al. · 2023 · Frontiers in Immunology
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D
Peter S. Linsley, Sarah Alice Long · 2019 · Current Opinion in Endocrinology Diabetes and Obesity
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus
Jia Liu, Yuequan Shi, Xiaoyan Liu, Dongming Zhang, Haoran Zhang, Minjiang Chen, Yan Xu, Jing Zhao, Wei Zhong, Mengzhao Wang · 2022 · Translational Oncology
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
James Randall Patrinely, Anna K. Dewan, Douglas Buckner Johnson · 2020 · BioDrugs
Diagnosis and management of immune‐related adverse effects of immune checkpoint therapy in the emergency department
Sai‐Ching J. Yeung, Aiham Z. Qdaisat, Patrick S. Chaftari, Demis N. Lipe, Jeffrey Merlin, Eva Rajha, Adriana H. Wechsler, Marcelo Sandoval, Jayne M. Viets-Upchurch, Aisha Al‐Breiki et al. · 2020 · Journal of the American College of Emergency Physicians Open
New Aspects of Diabetes Research and Therapeutic Development
Leslie S. Satin, Scott A. Soleimanpour, Emily M. Walker · 2021 · Pharmacological Reviews
Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
Almog Shalit, Panagiotis Sarantis, Evangelos Koustas, Eleni-Myrto Trifylli, Dimitris Matthaios, Michalis V. Karamouzis · 2023 · Cancers
Anti-pituitary antibodies as a marker of autoimmunity in pituitary glands
Shintaro Iwama, Hiroshi Arima · 2020 · Endocrine Journal
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
Calogera Claudia Spagnolo, G Giuffrida, Salvatore Cannavò, Tindara Franchina, Nicola Silvestris, Rosaria Maddalena Ruggeri, Mariacarmela Santarpía · 2022 · Cancers
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor–Induced Hypophysitis
Zoe Quandt, Stephanie J. Kim, Javier E. Villanueva-Meyer, Catherine Coupe, Arabella Young, Jee Hye Kang, Jinoos Yazdany, Gabriela Schmajuk, Stephanie Rush, Elad Ziv et al. · 2023 · Journal of the Endocrine Society
Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis
Fiamma Berner, Lukas Flatz · 2023 · Immunological Reviews
New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes
Miriam Cabello-Olmo, Miriam Araña, Ilian Radichev, Paul Smith, Eduardo Huarte, Miguel Barajas · 2019 · International Journal of Molecular Sciences
Type 1 diabetes induced by immune checkpoint inhibitors
Rui Zhang, Xiaoling Cai, Liu Liu, Xueyao Han, Linong Ji · 2020 · Chinese Medical Journal
Checkpoint blockade toxicities: Insights into autoimmunity and treatment
Michael J. Walsh, Michael Lawrence Dougan · 2021 · Seminars in Immunology
Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation
Lilia Bardoscia, Nadia Pasinetti, Luca Triggiani, Salvatore Cozzi, Angela Sardaro · 2021 · Frontiers in Pharmacology
Anti–PD-1 Therapy–Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma
Raynald A. Samoa, Hayley S. Lee, Sung Hee Kil, Bart O. Roep · 2020 · Diabetes Care
Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy
Linda Wu, Matteo Salvatore Carlino, David Alexander Brown, Georgina Venetia Long, Roderick John Clifton-Bligh, Rhiannon Mellor, Krystal Moore, Sarah Christina Sasson, Alexander Maxwell Menzies, Venessa Tsang et al. · 2023 · The Journal of Clinical Endocrinology & Metabolism
Insulin resistance and cancer: molecular links and clinical perspectives
Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo, Vincenzo Russo, Luca Rinaldi, Carlo Acierno, Maria Teresa Gemelli, Riccardo Ricotta, Ferdinando Carlo Sasso et al. · 2025 · Molecular and Cellular Biochemistry
Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: Beyond autoimmune insulin-dependent diabetes
Amanda Leiter, Emily Carroll, Danielle Brooks, Jennifer Ben Shimol, Elliot Eisenberg, Juan Pablo Wisnivesky, Matthew D. Galsky, Emily J. Gallagher · 2020 · Diabetes Research and Clinical Practice
Endocrine toxicity of cancer immunotherapy: clinical challenges
Bliss Anderson, Daniel L. Morganstein · 2021 · Endocrine Connections
Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody—insight into the pathogenesis of autoimmune endocrinopathy—
Sumie Okahata, Kentaro Sakamoto, Takako Mitsumatsu, Yuko Kondo, Shinsuke Noso, Hiroshi Ikegami, Teruo Shiba · 2019 · Endocrine Journal
Management of Acute Pancreatitis Associated With Checkpoint Inhibitors
CRNP Barbara Barnes Rogers, Terri Cuddahy, MPAS Carolyn Zawislak · 2020 · Journal of the Advanced Practitioner in Oncology
ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management
Yun Shi, Min Shen, Xuqin Zheng, Yang Chen, Ruiling Zhao, Yong Gu, Tao Yang · 2020 · The Journal of Clinical Endocrinology & Metabolism
Immune checkpoint inhibitor–induced diabetes mellitus with pembrolizumab
Anis Zand Irani, Ahmed Almuwais, Holly Gibbons · 2022 · BMJ Case Reports
PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review
Cuiping Lin, Xuan Li, Yu Qiu, Zheng Chen, Jianping Liu · 2022 · Frontiers in Public Health
Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes
Jiatong Ding, Kangping Yang, Kong-Lan Lin, Yu-Ke Cao, Fang Zou · 2023 · Frontiers in Endocrinology
Fulminant Type 1 Diabetes—East and West
Akihisa Imagawa, Toshiaki Hanafusa · 2023 · The Journal of Clinical Endocrinology & Metabolism
Role of B cells in immune‐related adverse events following checkpoint blockade
Kavita M. Dhodapkar, Alyssa M. Duffy, Madhav V. Dhodapkar · 2023 · Immunological Reviews
Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance
Tijana Martinov, Brian T. Fife · 2019 · Annals of the New York Academy of Sciences
Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy
Michael Lawrence Dougan · 2020 · Cancer Immunology Research
Digestive Toxicities Secondary to Immune Checkpoint Inhibition Therapy – Reports of Rare Events. A Systematic Review
Liliana Rădulescu, Dana Crișan, Cristiana Maria Grapa, Dan Rădulescu · 2021 · Journal of Gastrointestinal and Liver Diseases
Autoimmune Responses in Oncology: Causes and Significance
Halin Bareke, Pablo Juanes‐Velasco, Alicia Landeira‐Viñuela, Ángela‐Patricia Hernández, Juan Jesús Cruz, Lorena Bellido, Emilio Fonseca, Alfonssina Niebla Cárdenas, Enrique Montalvillo, Rafael Góngora et al. · 2021 · International Journal of Molecular Sciences
A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis
Lin Zhou, Shuhui Yang, Youtao Li, Cheng Xue, Renping Wan · 2024 · Frontiers in Immunology
Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
Fumika Kamitani, Yuichi Nishioka, Miyuki Koizumi, Hiroki Nakajima, Yukako Kurematsu, Sadanori Okada, Shinichiro Kubo, Tomoya Myojin, Tatsuya Noda, Tomoaki Imamura et al. · 2024 · Journal of Diabetes Investigation
Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
Amy L. Zhang, Fang Wang, Lee‐Shing Chang, Marie Elizabeth McDonnell, Le Min · 2021 · Frontiers in Endocrinology
Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1 / JAK2 inhibitor
Tingting Ge, Amber‐Lee Phung, Gaurang Jhala, Prerak Trivedi, Nicola Principe, David J. De George, Evan G. Pappas, Sara A. Litwak, Laura Sanz‐Villanueva, Tara Catterall et al. · 2022 · Clinical & Translational Immunology
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
Jasmine I. Caulfield, Lilach Aizenbud, Ana Luisa Perdigoto, Eric Meffre, Lucia B. Jilaveanu, Dominika A. Michalek, Stephen S. Rich, Yariv Aizenbud, Adebowale Adeniran, Kevan C. Herold et al. · 2023 · Journal for ImmunoTherapy of Cancer
Autoimmune pancreatitis after nivolumab anti–programmed death receptor-1 treatment
Léa Dehghani, Nidaa Mikaïl, N. Kramkimel, Philippe A. Soyer, Rachida Lebtahi, Roberto Mallone, Étienne Larger · 2018 · European Journal of Cancer
Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
Yue Zhang, Yisheng V. Fang, Jianhua Wu, Genjie Huang, Jianping Bin, Yulin Liao, Min Shi, Wangjun Liao, Na Huang · 2022 · Frontiers in Pharmacology
Rapid onset type 1 diabetes with anti-PD-1 directed therapy
Karen M. Yun, Gregory A. Daniels, Kathryn Ann Gold, Karen Clare McCowen, Sandip Pravin Patel · 2020 · Oncotarget
Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions
Kieran Oldfield, Rohan Jayasinghe, Selvanayagam Niranjan, Sameer Chadha · 2021 · BMJ Case Reports
Patient-Centered Diabetes Care of Cancer Patients
A. Kotwal, Y. Cheung, G. Cromwell, A. Drincic, H. Leblebjian, Z. Quandt, Robert J. Rushakoff, M. McDonnell · 2021 · Current Diabetes Reports
Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review
Carlo Augusto Mallio, Caterina Bernetti, Laura Cea, Andrea Buoso, Massimo Stiffi, Daniele Vertulli, Federico Greco, Bruno Beomonte Zobel · 2023 · Current Oncology
Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors
Deepika Satish, I‐Hsin Lin, James Flory, Hans Gerdes, Michael Andrew Postow, David M. Faleck · 2023 · The Oncologist
Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival
Lisa Y. Yang, Sruthi Murthy, Alessio Cortellini, Emma Lim, Michael Gonzalez, David James Pinato, Mariana Abdel-Malek, Sarah Mahmoud, Niamh M. Martin · 2024 · Frontiers in Endocrinology
Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus
Eleni-Rafaela Kani, Eleftheria Karaviti, Dimitra Karaviti, Eleni Gerontiti, Ioanna A. Paschou, Katerina Saltiki, Katerina Stefanaki, Θεοδώρα Ψαλτοπούλου, Stavroula Α. Paschou · 2024 · Endocrine
Targeting Type 1 Diabetes: Selective Approaches for New Therapies
Daniel F. Sheehy, Sean P. Quinnell, Arturo J. Vegas · 2019 · Biochemistry
Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes
Tijana Martinov, Linnea A. Swanson, Elise R. Breed, Christopher Tucker, Alexander J. Dwyer, Jenna K. Johnson, Jason S. Mitchell, Nathanael L. Sahli, Joseph C Wilson, Lovejot M. Singh et al. · 2019 · The Journal of Immunology